A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13 [PDF]
In this case report, we describe for the first time a patient with thrombotic thrombocytopaenic purpura (TTP) accompanying highly active systemic lupus erythematosus (SLE) that was associated with non-neutralizing antibodies against the plasma ...
Ferrari, Silvia +4 more
core
Primary Thrombotic Microangiopathy in Pediatric Patients
Background . Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology .
Andrés David Aranzazu Ceballos MD +5 more
doaj +1 more source
Complement hyperactivation and thrombotic microangiopathy are closely associated with severe COVID-19. Endothelial dysfunction is a key mechanism underlying thrombotic microangiopathy.
Jian Wu +14 more
doaj +1 more source
Thrombotic microangiopathy is a pathological condition caused by several factors including drugs, and characterized by endothelial injury and small vessel occlusion. It may cause severe acute kidney injury.
Sibel ERSAN +3 more
doaj
Case Report: Avermectin poisoning-associated hemolytic uremic syndrome
Avermectin, a commonly used agricultural pesticide and antiparasitic agent, typically causes acute human toxicity characterized by central nervous system depression and gastrointestinal disturbances.
Jianping Xiao +4 more
doaj +1 more source
Clinical Dilemma in the Treatment of a Patient with Microangiopathic Haemolytic Anaemia, Thrombocytopaenia and Severe Hypertension [PDF]
While haemolytic uraemic syndrome in children is predominantly associated with Shiga toxin -producing Escherichia coli (typically 0157:H7), some cases occur without associated diarrhoea, or as the manifestation of an underlying disorder other than ...
Castro, I, Gomes, D, Viegas, V
core
Atypical haemolytic-uraemic syndrome caused by factor H mutation: case report and new management strategies in children [PDF]
Atypical haemolytic uraemic syndrome is causedby alternative complement pathway dysregulation. It has recently been recognised that most cases are due to genetic factors and a growing list of mutations has been described.
Araújo, L. +5 more
core
Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom [PDF]
, +4 more
core +1 more source
Thrombotic microangiopathy associated with use of interferon-beta
Teresa Olea,1 Raquel Díaz-Mancebo,1 Maria-Luz Picazo,2 Jorge Martínez-Ara,1 Angel Robles,3 Rafael Selgas,11Departments of Nephrology, 2Pathology, 3Internal Medicine, Hospital Universitario La Paz, Madrid, SpainAbstract: Interferon ...
Robles A +5 more
doaj
Evolution of biological agents: how established drugs can become less safe [PDF]
Casadevall, Nicole +2 more
core +1 more source

